Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
181.49M | 167.13M | 131.31M | 196.25M | 277.13M | 186.42M | Gross Profit |
150.14M | 156.06M | 96.27M | 143.42M | 214.96M | 156.00M | EBIT |
-61.81M | -22.61M | 11.94M | -25.50M | 78.89M | 8.55M | EBITDA |
-122.11M | 40.79M | 101.73M | 54.41M | 133.16M | 69.05M | Net Income Common Stockholders |
-132.62M | -4.03M | 52.15M | -5.22M | 57.14M | -2.98M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
256.17M | 256.17M | 170.31M | 211.87M | 341.11M | 411.19M | Total Assets |
941.77M | 941.77M | 787.22M | 762.67M | 1.30B | 1.36B | Total Debt |
7.11M | 7.11M | 6.17M | 87.75M | 336.26M | 454.53M | Net Debt |
-65.20M | -65.20M | -16.79M | 87.70M | 316.74M | 406.91M | Total Liabilities |
111.33M | 111.33M | 86.30M | 165.18M | 479.75M | 652.76M | Stockholders Equity |
830.44M | 830.44M | 700.91M | 597.49M | 821.63M | 709.52M |
Cash Flow | Free Cash Flow | ||||
35.51M | 95.23M | -4.27M | 119.93M | 70.04M | 50.13M | Operating Cash Flow |
52.81M | 97.05M | 49.58M | 137.85M | 78.80M | 54.59M | Investing Cash Flow |
-135.00M | -143.66M | -11.68M | 163.62M | 30.52M | 231.65M | Financing Cash Flow |
80.39M | 97.57M | -59.95M | -275.99M | -137.76M | -310.55M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
55 Neutral | $1.97B | 48.01 | -16.56% | ― | 53.40% | -230.86% | |
54 Neutral | $1.84B | ― | -33.98% | ― | 449.03% | 42.86% | |
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% | |
53 Neutral | $2.24B | ― | -33.06% | ― | 69.31% | 57.12% | |
49 Neutral | $2.17B | ― | -27.85% | ― | ― | -94.92% | |
43 Neutral | $2.12B | ― | -33.43% | ― | ― | 4.80% | |
40 Underperform | $1.61B | ― | -316.82% | ― | ― | -65.63% |
On April 17, 2025, Ligand Pharmaceuticals announced a merger agreement between its subsidiaries, Pelthos Therapeutics and LNHC, Inc., and Channel Therapeutics Corporation. The merger, supported by $50 million in equity capital, aims to enhance the commercialization of ZELSUVMI, an FDA-approved topical gel for Molluscum contagiosum, and will see the combined company operate under the name Pelthos Therapeutics Inc. The transaction is expected to close in the summer of 2025, with Ligand entitled to a 13% royalty on worldwide sales of ZELSUVMI. This strategic move is anticipated to deliver significant value to shareholders and advance Channel’s existing NaV 1.7 programs.